Clonogenicity-based radioresistance determines the expression of immune suppressive immune checkpoint molecules after hypofractionated irradiation of MDA-MB-231 triple-negative breast cancer cells

被引:1
作者
Gehre, Simon [1 ,2 ,3 ]
Meyer, Felix [4 ]
Sengedorj, Azzaya [1 ,2 ,3 ]
Grottker, Fridolin [1 ,2 ,3 ]
Reichardt, Clara M. [1 ,2 ,3 ]
Alomo, Jannik [1 ,2 ,3 ]
Borgmann, Kerstin [4 ]
Frey, Benjamin [1 ,2 ,3 ]
Fietkau, Rainer [2 ,3 ]
Rueckert, Michael [1 ,2 ,3 ]
Gaipl, Udo S. [1 ,2 ,3 ]
机构
[1] Friedrich Alexander Univ Erlangen Nurnberg, Dept Radiat Oncol, Translat Radiobiol, Univ Klinikum Erlangen, Erlangen, Germany
[2] Friedrich Alexander Univ Erlangen Nurnberg, Dept Radiat Oncol, Univ Klinikum Erlangen, Erlangen, Germany
[3] Comprehens Canc Ctr Erlangen EMN, Erlangen, Germany
[4] Univ Med Ctr Hamburg Eppendorf, Ctr Oncol, Dept Radiotherapy & Radiat Oncol, Lab Radiobiol & Expt Radiooncol, Hamburg, Germany
来源
FRONTIERS IN ONCOLOGY | 2023年 / 13卷
基金
欧盟地平线“2020”;
关键词
radiotherapy; breast cancer; radioresistance; immune checkpoint molecules; dendritic cells; tumor cell death; FRACTIONATED RADIOTHERAPY; POTENTIAL MECHANISM; RADIATION-THERAPY; PD-L1; IMMUNOTHERAPY; APOPTOSIS; RELEASE; B7-H1; DEATH; HSP70;
D O I
10.3389/fonc.2023.981239
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Only a subset of patients with triple-negative breast cancer (TNBC) benefits from a combination of radio- (RT) and immunotherapy. Therefore, we aimed to examine the impact of radioresistance and brain metastasizing potential on the immunological phenotype of TNBC cells following hypofractionated RT by analyzing cell death, immune checkpoint molecule (ICM) expression and activation of human monocyte-derived dendritic cells (DCs). MDA-MB-231 triple-negative breast cancer tumor cells were used as model system. Apoptosis was the dominant cell death form of brain metastasizing tumor cells, while Hsp70 release was generally significantly increased following RT and went along with necrosis induction. The ICMs PD-L1, PD-L2, HVEM, ICOS-L, CD137-L and OX40-L were found on the tumor cell surfaces and were significantly upregulated by RT with 5 x 5.2 Gy. Strikingly, the expression of immune suppressive ICMs was significantly higher on radioresistant clones compared to their respective non-radioresistant ones. Although hypofractionated RT led to significant cell death induction and release of Hsp70 in all tumor cell lines, human monocyte-derived DCs were not activated after co-incubation with RT-treated tumor cells. We conclude that radioresistance is a potent driver of immune suppressive ICM expression on the surface of TNBC MDA-MB-231 cells. This mechanism is generally known to predominantly influence the effector phase, rather than the priming phase, of anti-tumor immune responses.
引用
收藏
页数:12
相关论文
共 63 条
  • [1] Adams S, 2019, ANN ONCOL, V30, P405, DOI [10.1093/annonc/mdy518, 10.1093/annonc/mdy517]
  • [2] The Role of Cancer Stem Cells in Radiation Resistance
    Arnold, Christoph Reinhold
    Mangesius, Julian
    Skvortsova, Ira-Ida
    Ganswindt, Ute
    [J]. FRONTIERS IN ONCOLOGY, 2020, 10
  • [3] Bentzen SM, 2008, LANCET, V371, P1098, DOI 10.1016/S0140-6736(08)60348-7
  • [4] Analysis of clonogenic growth in vitro
    Brix, Nikko
    Samaga, Daniel
    Belka, Claus
    Zitzelsberger, Horst
    Lauber, Kirsten
    [J]. NATURE PROTOCOLS, 2021, 16 (11) : 4963 - 4991
  • [5] Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial
    Brunt, Adrian Murray
    Haviland, Joanne S.
    Wheatley, Duncan A.
    Sydenham, Mark A.
    Alhasso, Abdulla
    Bloomfield, David J.
    Chan, Charlie
    Churn, Mark
    Cleator, Susan
    Coles, Charlotte E.
    Goodman, Andrew
    Harnett, Adrian
    Hopwood, Penelope
    Kirby, Anna M.
    Kirwan, Cliona C.
    Morris, Carolyn
    Nabi, Zohal
    Sawyer, Elinor
    Somaiah, Navita
    Stones, Liba
    Syndikus, Isabel
    Bliss, Judith M.
    Yarnold, John R.
    [J]. LANCET, 2020, 395 (10237) : 1613 - 1626
  • [6] Cortes J, 2020, LANCET, V396, P1817, DOI 10.1016/S0140-6736(20)32531-9
  • [7] Combining Radiotherapy and Immunotherapy in Metastatic Breast Cancer: Current Status and Future Directions
    David, Steven
    Tan, Jennifer
    Siva, Shankar
    Karroum, Lama
    Savas, Peter
    Loi, Sherene
    [J]. BIOMEDICINES, 2022, 10 (04)
  • [8] STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors
    Deng, Liufu
    Liang, Hua
    Xu, Meng
    Yang, Xuanming
    Burnette, Byron
    Arina, Ainhoa
    Li, Xiao-Dong
    Mauceri, Helena
    Beckett, Michael
    Darga, Thomas
    Huang, Xiaona
    Gajewski, Thomas F.
    Chen, Zhijian J.
    Fu, Yang-Xin
    Weichselbaum, Ralph R.
    [J]. IMMUNITY, 2014, 41 (05) : 843 - 852
  • [9] Chemoradiation Increases PD-L1 Expression in Certain Melanoma and Glioblastoma Cells
    Derer, Anja
    Spiljar, Martina
    Baeumler, Monika
    Hecht, Markus
    Fietkau, Rainer
    Frey, Benjamin
    Gaipl, Udo S.
    [J]. FRONTIERS IN IMMUNOLOGY, 2016, 7
  • [10] Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study
    Dirix, Luc Y.
    Takacs, Istvan
    Jerusalem, Guy
    Nikolinakos, Petros
    Arkenau, Hendrik-Tobias
    Forero-Torres, Andres
    Boccia, Ralph
    Lippman, Marc E.
    Somer, Robert
    Smakal, Martin
    Emens, Leisha A.
    Hrinczenko, Borys
    Edenfield, William
    Gurtler, Jayne
    von Heydebreck, Anja
    Grote, Hans Juergen
    Chin, Kevin
    Hamilton, Erika P.
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2018, 167 (03) : 671 - 686